Latest News - Novartis

Thursday, July 19, 2018

Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitis

Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development …

Read the full story

Thursday, June 21, 2018

FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsA

The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 v…

Read the full story

Thursday, May 24, 2018

Psoriatic Arthritis Awareness Project Launches

In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awa…

Read the full story

Tuesday, May 01, 2018

FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanoma

The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected …

Read the full story

Wednesday, April 04, 2018

GlobalData: Sun Pharma’s Ilumya To Face Strong Competition in the US market

It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from GlobalData, a leading data and analytics company.

 In March 2018 the US Food and Drug…

Read the full story

Tuesday, March 06, 2018

Novartis' Xolair Recommended in New Global Chronic Urticaria Guideline

A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not respondi…

Read the full story

Thursday, February 08, 2018

FDA Approves Cosentyx Label Update to Include Scalp Psoriasis

The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label inc…

Read the full story

Wednesday, September 13, 2017

Five-Year Data Show Sustained Efficacy, Safety for Cosentyx

Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase …

Read the full story

Monday, March 06, 2017

Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humira

Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. …

Read the full story

Thursday, July 14, 2016

FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandoz

The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five in…

Read the full story

Wednesday, June 29, 2016

Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasis

Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have su…

Read the full story

Friday, March 18, 2016

Study Links Psoriasis to Bone Loss. Is IL-17 to Blame?

Psoriasis is linked to widespread bone loss, according to Researchers from the Genes, Development and Disease Group at the Spanish National Cancer Research Centre (CNIO) in Madrid. The new study, w…

Read the full story

Friday, February 12, 2016

Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in US

Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights …

Read the full story

Thursday, January 28, 2016

Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Education

Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the differen…

Read the full story

Wednesday, January 20, 2016

FDA Approves Two New indications for Cosentyx

The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). …

Read the full story
Load More